These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 16282658)

  • 1. A small step for science, a big one for commerce.
    Birkett L
    Stud Health Technol Inform; 2005; 117():101-3. PubMed ID: 16282658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. You have an idea, now what?
    Gertner M
    Semin Pediatr Surg; 2006 Nov; 15(4):302-8. PubMed ID: 17055961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Largest biotechnology companies.
    Mod Healthc; 2013 Sep; 43(39):34. PubMed ID: 24199305
    [No Abstract]   [Full Text] [Related]  

  • 4. The role of the independent clinical laboratory in new assay development and commercialization.
    Ellis DG
    Clin Leadersh Manag Rev; 2003; 17(6):331-2. PubMed ID: 14692076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fundraising initiatives and vendor solicitation: avoiding kickback implications.
    Gordon L
    Health Care Law Mon; 2007 Mar; ():3-6. PubMed ID: 17460840
    [No Abstract]   [Full Text] [Related]  

  • 6. The MTA-rip it up and start again?
    Ku K; Henderson J
    Nat Biotechnol; 2007 Jul; 25(7):721-4. PubMed ID: 17621290
    [No Abstract]   [Full Text] [Related]  

  • 7. Affordability of New Technologies: The Next Frontier.
    Towse A; Mauskopf JA
    Value Health; 2018 Mar; 21(3):249-251. PubMed ID: 29566829
    [No Abstract]   [Full Text] [Related]  

  • 8. Healthcare has that IT factor. Xerox latest company to seek entry into market with proposed ACS deal.
    Conn J
    Mod Healthc; 2009 Oct; 39(40):14. PubMed ID: 19873887
    [No Abstract]   [Full Text] [Related]  

  • 9. The future of telemedicine & its Faustian reliance on regulatory trade barriers for protection.
    McLean TR
    Health Matrix Clevel; 2006; 16(2):443-509. PubMed ID: 16948249
    [No Abstract]   [Full Text] [Related]  

  • 10. Technology transfer. Universities find too many strings attached to foundation's offer.
    Holden C
    Science; 2006 May; 312(5777):1127. PubMed ID: 16728608
    [No Abstract]   [Full Text] [Related]  

  • 11. Why are we copyrighting science?
    de Silva V; Hanwella R
    BMJ; 2010 Sep; 341():c4738. PubMed ID: 20847026
    [No Abstract]   [Full Text] [Related]  

  • 12. Stem cell biotech: seeking a piece of the action.
    Parson AB
    Cell; 2008 Feb; 132(4):511-3. PubMed ID: 18295564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medical technologies can carry big payoff, big costs. How to assess needs and build strategies.
    Carpenter D
    Trustee; 2008; 61(7):8-12, 14, 19 passim. PubMed ID: 18773556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The origin of informed consent].
    Mallardi V
    Acta Otorhinolaryngol Ital; 2005 Oct; 25(5):312-27. PubMed ID: 16602332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biotechnology and the spirit of capitalism.
    Cohen E
    New Atlantis; 2006; 12():9-23. PubMed ID: 16832952
    [No Abstract]   [Full Text] [Related]  

  • 16. Turning basic science discoveries into successful commercial opportunities.
    van Rooij E
    Cardiovasc Res; 2019 Oct; 115(12):e127-e129. PubMed ID: 31364701
    [No Abstract]   [Full Text] [Related]  

  • 17. Health-related biotechnology in Africa: managing the legislative and regulatory issues.
    Andanda AP
    Afr J Med Med Sci; 2007; 36 Suppl():55-61. PubMed ID: 17703566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Equity in sharing science and the ownership of knowledge.
    Kidson C
    Southeast Asian J Trop Med Public Health; 1999 Sep; 30(3):397-8. PubMed ID: 10774641
    [No Abstract]   [Full Text] [Related]  

  • 19. Access to tangible research materials in biomedical research: conditions of access and their effect on research.
    Monotti AL
    J Law Med; 2006 Aug; 14(1):86-101. PubMed ID: 16937783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is rate of return pricing a useful approach when value-based pricing is not appropriate?
    Drummond M; Towse A
    Eur J Health Econ; 2019 Sep; 20(7):945-948. PubMed ID: 30771033
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.